Evidence map›Paper›PMID 32384736›Full record

ArticleInternational journal of molecular sciences2020

Ina Felix, Santosh K Lomada, Holger Barth, Thomas Wieland

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. TheToxins · 2023
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ina FelixInstitute of Pharmacology and Toxicology, University Ulm Medical Center, 89081 Ulm, Germany.
Santosh K LomadaExperimental Pharmacology, European Center for Angioscience, Mannheim Medical Faculty, Heidelberg University, 68167 Mannheim, Germany.
Holger BarthInstitute of Pharmacology and Toxicology, University Ulm Medical Center, 89081 Ulm, Germany.
Thomas WielandExperimental Pharmacology, European Center for Angioscience, Mannheim Medical Faculty, Heidelberg University, 68167 Mannheim, Germany.
Heidelberg University · DEUniversität Ulm · DE

Funding

Deutsche Forschungsgemeinschaft 316249678- SFB 1279 (project C02)Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg PharmCompNet
6 · The paper itself

Abstract

Some highly metastatic types of breast cancer show decreased intracellular levels of the tumor suppressor protein NME1, also known as nm23-H1 or nucleoside diphosphate kinase A (NDPK-A), which decreases cancer cell motility and metastasis. Since its activity is directly correlated with the overall outcome in patients, increasing the cytosolic levels of NDPK-A/NME1 in such cancer cells should represent an attractive starting point for novel therapeutic approaches to reduce tumor cell motility and decrease metastasis. Here, we established the

Indexed as

Antigens, BacterialBacterial ToxinsBreast NeoplasmsCell Line, TumorCell MovementCytosolDrug CarriersFemaleHumansNM23 Nucleoside Diphosphate KinasesRecombinant Proteinsanthrax toxinAntigens, BacterialBacterial ToxinsDrug CarriersNM23 Nucleoside Diphosphate KinasesNME1 protein, humanRecombinant Proteinsanthrax toxinNDPK-ANm23-H1NME1protective antigen PA63protein transporttargeted drug deliverytumor metastasis suppressor protein

Identifiers

PMID32384736
PMCPMC7246847
OpenAlexW3020829243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.